Logo-bi
BioImpacts. 2021;11(1): 5-14.
doi: 10.34172/bi.2021.02
  Abstract View: 190
  PDF Download: 109

Original Research

Impact of RAS/RAF mutations on clinical and prognostic outcomes in metastatic colorectal cancer

Roya Dolatkhah 1 ORCID logo, Saeed Dastgiri 2 ORCID logo, Amir Taher Eftekhar Sadat 3, Faris Farassati 4, Marzieh Nezamdoust 5, Mohammad Hossein Somi 3* ORCID logo

1 Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Tabriz Health Services Management Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Midwest Biomedical Research Foundation, Kansas City, MO, USA
5 Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Introduction: Early-activated RAS/RAF mutation status is a key molecular finding in colorectal cancer (CRC), while these mutations have been proposed as predictive and prognostic biomarkers. The present study has been designed as a longitudinal study to evaluate and summarize the different genotypes of metastatic CRC (mCRC), and assessing any association with the disease prognosis and clinicopathological characteristics. This study was performed in two main referral hospitals of Tabriz University of Medical Sciences, over three years (2016-2018).
Methods: Mutations were detected by Idylla tests of KRAS/NRAS/BRAF among a total of 173 mCRCs, using surgically-resected specimens or biopsied samples. To evaluate the factors associated with overall survival (OS) and prognosis, the Cox proportional hazards model was used in two steps to estimate the outcome measures (hazard ratio, or HR) with a 95% confidence interval (CI).
Results: The nominal 1 to 5-year OS rates were 78%, 65%, 55%, 46%, and 42%, respectively. KRAS mutations in codon 12 was an independent significant prognostic factor, as the patients with codon 12 mutations had a significantly lower OS (P Log-rank=0.049) and a higher hazard of mortality (HR=2.30; 95% CI: 0.95-5.58; P=0.066). Also, the mCRC patients with liver metastasis (HR=2.49; 95% CI: 1.49-12.52; P=0.002) and tumors of the distal colon (HR=3.36; 95% CI: 1.07-10.49; P=0.037) had a significantly worse prognosis.
Conclusion: KRAS mutation in codon 12 was an independent significant poor prognostic factor, and patients with liver metastasis had a significantly worse prognosis. Routinely performing specific oncogenic tests may help improve the patients’ prognosis and life expectancy.

Keywords: Colorectal cancer, Overall survival, Oncogene, KRAS, Hazard ratio
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 190

Your browser does not support the canvas element.


PDF Download: 109

Your browser does not support the canvas element.

Submitted: 22 Jul 2019
Revision: 10 Nov 2019
Accepted: 24 Nov 2019
ePublished: 20 Dec 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)